{"id":"secukinumab-150-milligram-cosentyx","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nasopharyngitis"},{"rate":"8-12","effect":"Upper respiratory tract infection"},{"rate":"5-8","effect":"Diarrhea"},{"rate":"2-4","effect":"Candida infection"},{"rate":"3-6","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-17A is a pro-inflammatory cytokine produced by T cells that drives inflammation in autoimmune and inflammatory conditions. By neutralizing IL-17A, secukinumab reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing the inflammatory cascade. This mechanism is particularly effective in conditions driven by Th17 cell-mediated immunity, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.","oneSentence":"Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:16.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Non-radiographic axial spondyloarthritis"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Secukinumab 300 milligram [Cosentyx]"],"phase":"marketed","status":"active","brandName":"Secukinumab 150 milligram [Cosentyx]","genericName":"Secukinumab 150 milligram [Cosentyx]","companyName":"Professor Mikkel Østergaard","companyId":"professor-mikkel-stergaard","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}